The landmark approval of sipuleucel-T in 2010 substantiated the viability of prostate cancer immunotherapy, providing level I evidence of a survival benefit in metastatic CRPC despite minimal changes in conventional endpoints such as PSA or imaging responses [65]. This evidence concerns the gene KLK3 and prostate carcinoma.